LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・MiNK Therapeutics
Search

MiNK Therapeutics

Gesloten

11.67 0.6

Buy

Prijsupdate 10 jun 2026, 19:55 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.21

Max

12

Belangrijke statistieken

By Trading Economics

Inkomsten

12B

-2.7M

EPS

-0.57

Werknemers

15

EBITDA

-289K

-2.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+196.11% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.9M

57M

Vorige openingsprijs

11.07

Vorige sluitingsprijs

11.67

MiNK Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

Lezen

10 jun 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

Lezen

10 jun 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

Lezen

10 jun 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

Lezen

10 jun 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

Lezen

10 jun 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

Lezen

10 jun 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

Lezen

10 jun 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

Lezen

10 jun 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

Lezen

10 jun 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

Lezen

10 jun 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

Lezen

10 jun 2026, 23:38 UTC

Global Equities Roundup: Market Talk

Lezen

10 jun 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

Lezen

10 jun 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

Lezen

10 jun 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

Lezen

10 jun 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

Lezen

10 jun 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

Lezen

10 jun 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

Lezen

10 jun 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

Lezen

10 jun 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

Lezen

10 jun 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

Lezen

10 jun 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

Lezen

10 jun 2026, 20:50 UTC

Financial Services Roundup: Market Talk

Lezen

10 jun 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

Lezen

10 jun 2026, 20:50 UTC

Health Care Roundup: Market Talk

Lezen

10 jun 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

Lezen

10 jun 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

Lezen

10 jun 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

Lezen

10 jun 2026, 20:33 UTC

Global Equities Roundup: Market Talk

Lezen

10 jun 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Lezen

Peer Vergelijking

Prijswijziging

MiNK Therapeutics Prognose

Koersdoel

By TipRanks

196.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35 USD  196.11%

Hoogste 35 USD

Laagste 35 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor MiNK Therapeutics - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan MiNK Therapeutics - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat